Skip to main content
AAO-HNSF 2025 Annual Meeting & OTO EXPO Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Rate ePoster
Video

Head and Neck Surgery

(A530) Da Vinci 5 in Transoral Robotic Surgery, First Impressions

Monday, October 13, 2025
12:00 PM - 1:00 PM EDT
Location: OTO EXPO, Posters

    Presenting Author(s)

  • Jakkree Naruekon, MD

    Research Fellow, Department of Otolaryngology - Head & Neck Surgery
    NYU Langone Health
    New York, New York, United States

    • Co-Author(s)

  • Gabriel D. Pujol, MD

    Head & Neck Oncologic and Microvascular Surgery; Facial Plastic & Reconstructive Surgery
    NYU Langone Health
    Guaynabo, Puerto Rico, United States

    • Senior Author(s)

  • UD

    Umamaheswar Duvvuri, MD, PhD

    Mendik Foundation Professor & Chair, Department of Otolaryngology
    NYU Langone Health
    New York, New York, United States

    • Co-Author(s)

  • AV

    Alec Vaezi, MD, PhD

    Clinical Associate Professor & Chief, Department of Otolaryngology - Head & Neck Surgery
    NYU Langone Health / NYU Langone Hospital - Long Island
    Garden City, New York, United States

  • Melonie Nance, MD

    Associate Professor, Department of Otolaryngology - Head & Neck Surgery
    NYU Langone Health
    New York, New York, United States

  • aJ

    adam S. Jacobson, MD

    Director, Division of Head & Neck Surgery
    NYU Langone Health
    New York, New York, United States

Disclosure(s):
Gabriel D. Pujol, MD: No relevant relationships to disclose.
Alec Vaezi, MD, PhD: No relevant relationships to disclose.
Melonie Nance, MD: No relevant relationships to disclose.
Jakkree Naruekon, MD: No relevant relationships to disclose.


Introduction: The latest update on the surgical robot most used for Transoral Robotic Surgery (TORS), the Da Vinci, comes in the form of the Da Vinci 5. Currently, there is no literature about its use in TORS. This study aims to determine if the Da Vinci 5 is at least non-inferior and as safe as previous Da Vinci models.

Methods: All surgeries of the oropharynx performed utilizing the Da Vinci 5 surgical system at a single institution were included in this study. All patients were followed for at least 30 days following surgery. The metrics studied were patient demographics, surgical outcomes, complications, and readmissions.

Results: As total of 6 head and neck surgery cases were performed utilizing the Da Vinci 5 surgical system. Five of the cases were performed for malignancy and included 1 base of tongue mucoepidermoid carcinoma, 1 tonsil HPV-related SCC, 2 HPV-related SCC of unknown primary, and 1 base of tongue P16-negative SCC. One case was performed for lingual tonsillitis. All malignancy cases resulted in negative surgical margins. All patients were able to eat the next day, as established by our post-operative protocol. All patients were discharged in less than 3 days. No complications related to surgery were observed. No patients required readmission after surgery.

Conclusions: Our early experience has demonstrated that surgery of the oropharynx can be safely performed with the Da Vinci 5 surgical system. Patient outcomes and complication rates remain similar to those observed in our experience with the Da Vinci Xi and SP systems. Our results demonstrate that the Da Vinci 5 is at least non-inferior to previous models with regards to surgery of the oropharynx. Future studies investigating the use of the force feedback technology will allow us to determine the added benefits this new advance may bring.